VSTM Verastem, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1526119 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-193.7%
Net margin-178.4%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-88.0%
ROIC (approx.)—
Asset turnover0.49x
Leverage & solvency
Liabilities / assets95.6%
Debt / equity0.00x
Current ratio1.93x
Interest coverage-141.93x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $30.91M | $10.00M | — | $2.60M | $2.05M |
| R&D expense | $114.60M | $81.33M | $61.36M | $50.56M | $39.35M |
| SG&A expense | $81.15M | $43.62M | $30.73M | $24.98M | $24.11M |
| Operating income | -$170.13M | -$114.96M | -$92.08M | -$72.94M | -$61.41M |
| Interest expense | $1.14M | $4.56M | $4.14M | $2.14M | $9.97M |
| Pretax income | -$209.47M | -$130.45M | -$87.37M | -$73.81M | -$71.20M |
| Income tax | — | $185,000 | — | $0 | $0 |
| Net income | -$209.47M | -$130.64M | -$87.37M | -$73.81M | -$71.20M |
| EBITDA | -$170.10M | -$114.93M | -$92.02M | -$72.82M | -$61.20M |
| EPS (basic) | -3.02 | -3.66 | -3.96 | -4.57 | -4.90 |
| EPS (diluted) | -3.02 | -3.66 | -3.96 | -4.57 | -4.90 |
| Weighted avg. shares (diluted) | 69.31M | 35.71M | 22.05M | 16.14M | 14.54M |
| Balance sheet | |||||
| Cash & equivalents | $204.99M | $89.06M | $79.08M | $75.79M | $21.49M |
| Short-term investments | — | — | $59.22M | $12.96M | $79.00M |
| Inventory | $1.83M | — | — | — | — |
| Current assets | $223.41M | $94.96M | $143.68M | $92.87M | $105.74M |
| PP&E, net | — | $32,000 | $37,000 | $92,000 | $210,000 |
| Intangibles | $16.43M | — | — | — | — |
| Total assets | $246.44M | $101.54M | $149.72M | $95.05M | $108.66M |
| Current liabilities | $72.27M | $30.97M | $26.38M | $21.66M | $18.59M |
| Long-term debt | — | $40.72M | $40.09M | $24.53M | — |
| Total debt | — | $40.72M | $40.09M | $24.53M | — |
| Total liabilities | $189.25M | $130.43M | $71.19M | $47.66M | $21.10M |
| Shareholders' equity | $57.20M | -$28.89M | $57.37M | $47.39M | $87.56M |
| Net debt | — | -$48.34M | -$38.99M | -$51.26M | — |
| Shares outstanding | 77.74M | 44.78M | 25.28M | 16.71M | 185.29M |
| Cash flow statement | |||||
| Operating cash flow | -$137.51M | -$104.77M | -$86.46M | -$63.67M | -$53.50M |
| Capital expenditure | — | $28,000 | — | — | $196,000 |
| Free cash flow | — | -$104.80M | — | — | -$53.70M |
| Investing cash flow | -$9.62M | $59.97M | -$44.45M | $66.19M | $87,000 |
| Financing cash flow | $263.31M | $54.78M | $134.19M | $51.78M | $6.88M |
| Depreciation & amortization | $30,000 | $26,000 | $62,000 | $118,000 | $206,000 |
| Stock-based compensation | $9.40M | $7.34M | $5.86M | $6.05M | $7.71M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.